Gabapentin is a relatively new antiepileptic agent structurally similar to gammaaminobutyric acid (GABA), with unclear mechanisms of action and a good safety profile. It has been used in psychiatric practice with promising results for the treatment of several disorders (for example bipolar disorder [BD], schizoaffective disorder, obsessive-compulsive disorder [OCD] , social phobia, somatization disorder, and behavioural agitation in dementia) (1, 2) . With regard to aggressive behaviour, a few studies have reported significant improvement in behavioural and psychological symptoms among dementia patients (3, 4) . In one study, a young patient affected by intermittent explosive disorder, attentiondeficit hyperactivity disorder (ADHD), organic mood disorder secondary to a closed head injury, and simple partial seizure disorder was treated with gabapentin 1200 mg daily. After treatment, a decrease in frequency and intensity of violent episodes was observed (5) . We report a case of successful gababentin treatment of chronic impulsive-aggressive behaviour in a patient with severe borderline personality disorder (BPD).
Case Report
A 30-year-old man with a DSM-IV diagnosis of severe BPD was admitted to our residential psychiatric program because his clinical condition progressively worsened secondary to the abrupt breakup of the relationship with his girlfriend. At psychiatric examination he reported unstable interpersonal relationships, chronic feelings of loneliness, affective instability, impulse dyscontrol with periodic drug and alcohol abuse and bulimic episodes, recurrent self-mutilating acts, and chronic impulsivity and violence. He also showed intense depressive symptoms, with suicidal ideation, suspiciousness, and visual egodistonic hallucinations. Brain CT scan revealed mild diffused atrophy without defined focal damage, while EEG and laboratory tests were in the normal range. From the first day of hospitalization, treatment was started with paroxetine 40 mg daily and lorazepam 7.5 mg daily . In the next 3 weeks a progressive improvement of mood was observed, with full remission of suicidal ideation and visual hallucinations, but the impulsive-aggressive behaviour remained unchanged. In fact, he showed frequent episodes of violence against objects and people. He broke plates and glasses in the dining room almost every day, he slammed and kicked doors and furniture, he flung chairs along the corridors, and he hit other people. The episodes, usually related to the patient's frustration when his excessive requests to staff and other patients were not met, caused a worsening in the ward atmosphere. Other patients, feeling fearful and hostile toward him, started to avoid him, and he went around the ward alone. For that reason, during the fourth week of admission, we added divalproex 1500 mg daily (plasma level 61 mg/L) to the treatment; however, in the following month there was no improvement in the his behavioural dyscontrol. We therefore discontinued divalproex and started a trial with gabapentin 900 mg daily. Within 48 hours of gabapentin initiation, a quick and dramatic improvement in the impulsive-aggressive behaviour was observed, and a complete remission of symptoms was reported in the following 2 weeks. Gabapentin was well tolerated by the patient, and he did not show any side effects. The ward atmosphere and the interpersonal relationships among the patients improved. Forty-five days after gabapentin initiation, the clinical benefit was unchanged, and it was possible to refer the patient to the rehabilitation program for supported employment. In 2 months, no further episode of impulse dyscontrol was registered, and the patient was discharged. In the last psychiatric interview he stated, "Since I started taking this new drug I no longer lose control, and I'm sure that its because of this drug."
In treating impulsive-aggressive behaviour in patients with BPD, the efficacy of the neuroleptics, monoamine oxidase inhibitors (MAOIs), selective serotonin reuptake inhibitors (SSRIs), and mood stabilizers (for example, carbamazepine, lithium carbonate, and divalproex) has been reported (6,7). However, a Medline search between October 1, 1966, and October 31, 2001, did not yield any references to gabapentin use.
The following observations support the hypothesis that the improvement in this patient's chronic behavioural dyscontrol is associated with gabapentin use: first, his behaviour did not benefit from previous treatments, including divalproex; second, gabapentin initiation was followed a quick and steady improvement in the disorder. However, because different drugs were used to treat the patient's psychiatric disturbances (that is, lorazepam and paroxetine), it is difficult to ascertain if the amelioration was directly related to gabapentin alone or to possible pharmacologic interaction, especially with the SSRI (paroxetine). SSRIs have been reported to reduce violent behaviour in psychiatric patients (8, 9) . Although further studies are necessary to confirm our observation, this report suggests that gabapentin is a possible last-line alternative adjunct in the treatment of impulsive-aggressive behaviour in patients with BPD.
Assessing and Managing Compulsive Scratching in Schizophrenia With Chronic Renal Failure
Dear Editor:
Assessment, differential diagnosis, and management of compulsive scratching (CS) in medically ill patients with psychiatric disorders can be very complicated. This is because it is difficult to pinpoint the underlying mechanism, which is crucial for the treatment. We present the case of Mr A, a 48-year-old man with an established diagnosis of schizophrenia and chronic renal failure secondary to focal segmental glomerulosclerosi, who was admitted to our inpatient unit suffering mainly with the following 2 conditions: extreme CS that had led to missing skin-patches and bleeding from his scalp and the front part of his legs, and orthostatic hypotension so severe that he was unable to stand up and walk unaided safely.
Given his severe uremic medical status, a wide range of psychopathology was expected (1) but not detected. On admission, his medications for renal failure were bumetanide 5 mg once daily, metalozone 2.5 mg on alternate days, chlorpheniramine 4 mg 3 times daily, and ferrous sulphate 200 mg twice daily. His psychotropic medications were fluphenthixol decanoate (depot) 50 mg weekly IM and chlorpromazine 50 mg at night. His medical status was poor (hemoglobin 81 g/L, creatinine 877 umol/L, urea 50.9 mmol/L).
We explored 4 possible causes of the CS:
1. We considered whether the CS was an obsessive-compulsive spectrum phenomenon, for which the patient had already been started on paroxetine (40 mg daily, over 6 months), with no or minimal improvement.
2. We considered whether the symptom represented somatic hallucination-related CS, in which a patient may scratch in response to somatic hallucinations. We excluded this possibility because a detailed assessment of the patient's mental state revealed no evidence of psychotic symptoms. Further, there was no evidence of CS prior to the development of his renal failure, despite prior treatment for schizophrenia.
3. We considered whether the patient was experiencing uremic CS (pruritis). The precise underlying mechanism of this condition is poorly understood but may relate to secondary iron deficiency anaemia, associated electrolyte imbalance, or accumulations of toxins (2). 4. We considered whether the CS was due to other causes, including dermatological, allergic, and cholestatic hepatic disease.
We felt that possibility 3 was the most likely. We tapered down and discontinued chlorpromazine to improve orthostatic hypotension. We made no other changes or additions to the patient's pharmacotherapy. Mr A required an urgent fresh blood transfusion (1 L) in the nephrology unit. After 72 hours, he returned to the psychiatric unit with almost complete resolution of the CS, together with improvement of his medical status. However, his urea (49.5 mmol/L) and creatinine (896 umol/L) levels were only marginally altered. The improvement in CS remained during his stay in the inpatient unit. He was discharged with no further change in his pharmacotherapy because his mental state was stable, with no evidence of psychosis or other psychopathology.
The precise mechanism of improvement in CS after blood transfusion remains unclear. However, we suggest 2 possibilities: the chemical(s) which caused CS may have been diluted or destroyed after blood transfusion, or significantly improved anaemia led to the improvement in CS (3).
With such patients, it is first important to investigate and try to pinpoint the mechanism of CS. Therefore, clinicians should consider several possible causes, as listed above. Second, clinicians should choose the appropriate treatment option, depending on the CS mechanism identified. Third, if there is severe anemia, we suggest an early-admissionnephrology consultation and fresh blood transfusion.
